HUE062551T2 - Kapszulás készítmények - Google Patents

Kapszulás készítmények

Info

Publication number
HUE062551T2
HUE062551T2 HUE19889873A HUE19889873A HUE062551T2 HU E062551 T2 HUE062551 T2 HU E062551T2 HU E19889873 A HUE19889873 A HU E19889873A HU E19889873 A HUE19889873 A HU E19889873A HU E062551 T2 HUE062551 T2 HU E062551T2
Authority
HU
Hungary
Prior art keywords
capsule formulations
capsule
formulations
Prior art date
Application number
HUE19889873A
Other languages
English (en)
Inventor
Manmohan Reddy Leleti
Jay P Powers
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE062551(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of HUE062551T2 publication Critical patent/HUE062551T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE19889873A 2018-11-30 2019-11-27 Kapszulás készítmények HUE062551T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
HUE062551T2 true HUE062551T2 (hu) 2023-11-28

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19889873A HUE062551T2 (hu) 2018-11-30 2019-11-27 Kapszulás készítmények

Country Status (28)

Country Link
US (2) US20200170957A1 (hu)
EP (2) EP3886820B8 (hu)
JP (1) JP7342124B2 (hu)
KR (1) KR102586747B1 (hu)
CN (1) CN113164403A (hu)
AR (1) AR117219A1 (hu)
AU (1) AU2019389031B2 (hu)
BR (1) BR112021010285A2 (hu)
CA (1) CA3120999A1 (hu)
CL (1) CL2021001389A1 (hu)
CY (1) CY1126079T1 (hu)
DK (1) DK3886820T3 (hu)
ES (1) ES2943492T3 (hu)
FI (1) FI3886820T3 (hu)
HR (1) HRP20230551T1 (hu)
HU (1) HUE062551T2 (hu)
IL (1) IL283450B2 (hu)
LT (1) LT3886820T (hu)
MA (1) MA54318B1 (hu)
MD (1) MD3886820T2 (hu)
MX (1) MX2021006242A (hu)
PL (1) PL3886820T3 (hu)
PT (1) PT3886820T (hu)
RS (1) RS64250B1 (hu)
SG (1) SG11202105572UA (hu)
SI (1) SI3886820T1 (hu)
TW (1) TWI827745B (hu)
WO (1) WO2020112961A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
WO2023225533A1 (en) * 2022-05-19 2023-11-23 Dow Global Technologies Llc Use of peg-based interpolymer complexes for improved solubilization of bcs class ii drugs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
CN101065115A (zh) 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2010075257A1 (en) 2008-12-22 2010-07-01 Chemocentryx, Inc. C5ar antagonists
AU2011224558B2 (en) 2010-03-10 2014-02-27 Abbvie Ireland Unlimited Company Solid compositions
PL2585064T3 (pl) 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
WO2015118015A1 (en) 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
PL3200791T3 (pl) 2014-09-29 2020-08-10 Chemocentryx, Inc. Sposoby i produkty pośrednie w otrzymywaniu antagonistów C5AR
MX2018008624A (es) 2016-01-14 2018-12-10 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス,インコーポレイティド 可溶性C5aRアンタゴニスト
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
ES2893769T3 (es) 2017-04-03 2022-02-10 Inflarx Gmbh Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a
JP2021501175A (ja) 2017-10-30 2021-01-14 ケモセントリックス,インコーポレイティド 免疫調節剤としての重水素化化合物
WO2019089534A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
CN112423752A (zh) 2018-06-07 2021-02-26 凯莫森特里克斯股份有限公司 C5a拮抗剂和ANCA相关性血管炎的剂量和疗效
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations

Also Published As

Publication number Publication date
CY1126079T1 (el) 2023-11-15
US11951214B2 (en) 2024-04-09
KR20210098489A (ko) 2021-08-10
EP3886820B1 (en) 2023-04-12
IL283450B1 (en) 2024-02-01
CN113164403A (zh) 2021-07-23
EP3886820A4 (en) 2022-08-24
TW202038952A (zh) 2020-11-01
WO2020112961A1 (en) 2020-06-04
AU2019389031B2 (en) 2023-06-15
FI3886820T3 (fi) 2023-05-25
LT3886820T (lt) 2023-06-12
MD3886820T2 (ro) 2023-07-31
IL283450B2 (en) 2024-06-01
RS64250B1 (sr) 2023-06-30
SI3886820T1 (sl) 2023-07-31
PL3886820T3 (pl) 2023-08-14
EP4233850A2 (en) 2023-08-30
CL2021001389A1 (es) 2021-12-24
CA3120999A1 (en) 2020-06-04
PT3886820T (pt) 2023-05-24
MA54318B1 (fr) 2023-08-31
EP4233850A3 (en) 2023-09-20
IL283450A (en) 2021-07-29
MA54318A (fr) 2021-10-06
KR102586747B1 (ko) 2023-10-06
ES2943492T3 (es) 2023-06-13
EP3886820A1 (en) 2021-10-06
JP7342124B2 (ja) 2023-09-11
HRP20230551T1 (hr) 2023-08-18
AR117219A1 (es) 2021-07-21
JP2022510304A (ja) 2022-01-26
DK3886820T3 (da) 2023-05-15
SG11202105572UA (en) 2021-06-29
MX2021006242A (es) 2021-09-10
US20200170957A1 (en) 2020-06-04
AU2019389031A1 (en) 2021-06-17
EP3886820B8 (en) 2023-05-17
BR112021010285A2 (pt) 2021-08-17
TWI827745B (zh) 2024-01-01
US20220233453A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
IL273541A (en) formulations
IL268697A (en) Formulations
IL269630A (en) Niraprib formulations
IL270866A (en) Fixed-dose compounds
IL269621A (en) Niraparib formulations
IL273282A (en) Niraprib formulations
ZA202006570B (en) Pharmaceutical formulations
GB201707189D0 (en) Novel formulations
GB201809976D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
IL283450A (en) capsule formulations
GB201904338D0 (en) Fluorouracil-containing formulations
SG11202010792TA (en) Improved pharmaceutical formulations
GB201707187D0 (en) Novel formulations
IL271908A (en) Over-compressed pharmaceutical preparations
SG11202011823SA (en) Activator-nucleator formulations
ZAA201801557S (en) Capsule
ZAA201801556S (en) Capsule
GB201819028D0 (en) Butanol-based formulations
ZAF201800730S (en) Capsule
GB201806710D0 (en) Capsule
IL268195A (en) Solid fosmetpantothenate formulations
GB201808386D0 (en) Formulations
GB201804545D0 (en) Formulations
GB201803201D0 (en) Formulations